慢性肝病患者COVID-19结局的预测因素:美国多中心研究
该多中心观察性队列研究纳入美国21家机构978例慢性肝病合并COVID-19患者中的867例,分析全因死亡和重症COVID-19的独立预测因素。总体全因死亡率为14.0%,61.7%发生重症COVID-19;酒精相关肝病、失代偿期肝硬化和肝细胞癌是全因死亡的独立危险因素,西班牙裔和失代偿期肝硬化与重症COVID-19相关。
要点
- 慢性肝病合并COVID-19患者总体全因死亡率为14.0%,重症COVID-19发生率为61.7%。
- 酒精相关肝病、失代偿期肝硬化和肝细胞癌是全因死亡的独立危险因素。
- 西班牙裔和失代偿期肝硬化与重症COVID-19风险独立相关。
核心结论
- 慢性肝病合并COVID-19患者中,预测全因死亡的危险因素为酒精相关肝病、失代偿期肝硬化和肝细胞癌。
- 西班牙裔和失代偿期肝硬化与重症COVID-19相关。
- 研究结果有助于对慢性肝病合并COVID-19患者进行风险分层和个体化管理。
研究设计与样本
- 多中心观察性队列研究,覆盖美国21家机构。
- 纳入2020年3月1日至2020年5月30日期间实验室确诊COVID-19的成人慢性肝病患者。
- 978例患者中867例符合纳入标准,平均年龄56.9±14.5岁,55%为男性。
- 采用生存分析识别全因死亡和COVID-19相关死亡的独立预测因素,多因素logistic回归确定重症COVID-19风险。
主要发现
- 总体全因死亡率为14.0%(n=121),61.7%(n=535)发生重症COVID-19。
- 以腹泻或恶心/呕吐起病的患者更可能发生重症COVID-19。
- 与全因死亡独立相关的肝脏特异性因素:酒精相关肝病(HR 2.42,95%CI 1.29-4.55)、失代偿期肝硬化(HR 2.91,95%CI 1.70-5.00)、肝细胞癌(HR 3.31,95%CI 1.53-7.16)。
- 其他与全因死亡相关的因素包括年龄增加、糖尿病、高血压、慢性阻塞性肺疾病和当前吸烟。
- 与重症COVID-19独立相关的因素:西班牙裔(OR 2.33,95%CI 1.47-3.70)和失代偿期肝硬化(OR 2.50,95%CI 1.20-5.21)。
临床怎么用
- 原文结论指出,研究结果将有助于对慢性肝病合并COVID-19患者进行风险分层和个体化管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chronic liver disease (CLD) represents a major global health burden. We undertook this study to identify the factors associated with adverse outcomes in patients with CLD who acquire the novel coronavirus-2019 (COVID-19). METHODS: We conducted a multi-center, observational cohort study across 21 institutions in the United States (US) of adult patients with CLD and laboratory-confirmed diagnosis of COVID-19 between March 1, 2020 and May 30, 2020. We performed survival analysis to identify independent predictors of all-cause mortality and COVID-19 related mortality, and multivariate logistic regression to determine the risk of severe COVID-19 in patients with CLD. RESULTS: Of the 978 patients in our cohort, 867 patients (mean age 56.9 ± 14.5 years, 55% male) met inclusion criteria. The overall all-cause mortality was 14.0% (n = 121), and 61.7% (n = 535) had severe COVID-19. Patients presenting with diarrhea or nausea/vomiting were more likely to have severe COVID-19. The liver-specific factors associated with independent risk of higher overall mortality were alcohol-related liver disease (ALD) (hazard ratio [HR] 2.42, 95% confidence interval [CI] 1.29-4.55), decompensated cirrhosis (HR 2.91 [1.70-5.00]) and hepatocellular carcinoma (HCC) (HR 3.31 [1.53-7.16]). Other factors were increasing age, diabetes, hypertension, chronic obstructive pulmonary disease and current smoker. Hispanic ethnicity (odds ratio [OR] 2.33 [1.47-3.70]) and decompensated cirrhosis (OR 2.50 [1.20-5.21]) were independently associated with risk for severe COVID-19. CONCLUSIONS: The risk factors which predict higher overall mortality among patients with CLD and COVID-19 are ALD, decompensated cirrhosis and HCC. Hispanic ethnicity and decompensated cirrhosis are associated with severe COVID-19. Our results will enable risk stratification and personalization of the management of patients with CLD and COVID-19. Clinicaltrials.gov number NCT04439084.
引用
- Kim D, Adeniji N, Latt N, et al. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. Clin Gastroenterol Hepatol. 2020. PMID: 32950749. doi:10.1016/j.cgh.2020.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。